V-IMMUNE for Immune Thrombocytopenia (ITP) Study
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 1 year old.
- You must have a confirmed diagnosis of immune thrombocytopenia (ITP).
- Your platelet count must be very low (20,000 or less per cubic millimeter) at the start.
- You cannot be pregnant or breastfeeding.
- You must not have HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
This trial tests a new mRNA-based medicine called RXIM002 for people with immune thrombocytopenia (ITP) that has not improved with standard treatments. The goal is to see if it can safely help raise platelet counts and reduce bleeding risk.
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
This trial tests a new drug called GL-2045 for immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing low platelet counts and bleeding risks. The study checks if GL-2045 is safe and effective for people whose platelet counts haven't been controlled well enough with other treatments.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.